Concepedia

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó, Govinda J. Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan Wynne, Jeffrey S. Riesmeyer, Robert J. Heine,

The Lancet · 2021 · 642 citations · 29 references

DOI

Concepts

References

29

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.9K citations · Full text

, , +14

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.4K citations · Full text

, , +16

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

William C. Duckworth, Carlos Abraira, Thomas Moritz et al. · New England Journal of Medicine · 2008 · 4.8K citations · Full text

, , +14

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

, , +14